NASDAQ:HURA - Nasdaq - US8989201038 - Common Stock - Currency: USD
2.3
-0.13 (-5.35%)
The current stock price of HURA is 2.3 USD.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.7 | 349.84B | ||
AMGN | AMGEN INC | 13.22 | 154.98B | ||
GILD | GILEAD SCIENCES INC | 15.43 | 148.54B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 21.64 | 94.13B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 60.79B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.23B | ||
ARGX | ARGENX SE - ADR | 71.39 | 40.50B | ||
ONC | BEONE MEDICINES LTD-ADR | 4.5 | 31.19B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.84B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.28B | ||
INSM | INSMED INC | N/A | 20.78B | ||
NTRA | NATERA INC | N/A | 20.75B |
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
TUHURA BIOSCIENCES INC
10500 University Center Dr., Suite 110
Tampa FLORIDA US
Employees: 19
Phone: 18138756600
The current stock price of HURA is 2.3 USD. The price decreased by -5.35% in the last trading session.
The exchange symbol of TUHURA BIOSCIENCES INC is HURA and it is listed on the Nasdaq exchange.
HURA stock is listed on the Nasdaq exchange.
8 analysts have analysed HURA and the average price target is 12.33 USD. This implies a price increase of 435.87% is expected in the next year compared to the current price of 2.3. Check the TUHURA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TUHURA BIOSCIENCES INC (HURA) has a market capitalization of 107.06M USD. This makes HURA a Micro Cap stock.
TUHURA BIOSCIENCES INC (HURA) currently has 19 employees.
TUHURA BIOSCIENCES INC (HURA) has a support level at 2.27 and a resistance level at 2.55. Check the full technical report for a detailed analysis of HURA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HURA does not pay a dividend.
TUHURA BIOSCIENCES INC (HURA) will report earnings on 2025-10-06, after the market close.
TUHURA BIOSCIENCES INC (HURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.1).
The outstanding short interest for TUHURA BIOSCIENCES INC (HURA) is 9.37% of its float. Check the ownership tab for more information on the HURA short interest.
ChartMill assigns a fundamental rating of 2 / 10 to HURA. The financial health of HURA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months HURA reported a non-GAAP Earnings per Share(EPS) of -4.1. The EPS increased by 27.01% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -216.15% | ||
ROE | -321.03% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to HURA. The Buy consensus is the average rating of analysts ratings from 8 analysts.